Skip to main content
Premium Trial:

Request an Annual Quote

Revenues Down, Losses Up for Sequenom in Q1

NEW YORK, April 29 (GenomeWeb News) - Sequenom today reported dwindling revenues and increased losses for the first quarter.

 

Revenues totaled $5.1 million, down from $7.4 million during the same quarter last year. "We see the number of new account opportunities for high-throughput genotyping reaching saturation," said CFO Steve Zaniboni in a statement.

 

Sequenom's R&D expenses increased slightly, to $6 million, from $5.9 million during the year-ago quarter.

 

The company recorded a net loss of $9.9 million, or $.25 per share, up from $8.5 million, or $.22 per share, during the first quarter of 2003.

 

As of March 31, San Diego-based Sequenom had $59.5 million in cash, cash equivalents, short-term investments and restricted cash.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more